BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?
Authors:
- Thomas J. Van EeTEThomas J. Van Ee
- Heleen H. Van AckerHAHeleen H. Van Acker
- Tom G. Van OorschotTOTom G. Van Oorschot
- Viggo F. Van TendelooVTViggo F. Van Tendeloo
- Evelien L. SmitsESEvelien L. Smits
- Ghaith BakdashGBGhaith Bakdash
- Gerty SchreibeltGSGerty Schreibelt
- I. Jolanda M. De VriesIVI. Jolanda M. De Vries
Open Access
Abstract
Dendritic cell (DC) vaccines show promising effects in cancer immunotherapy. However, their efficacy is affected by a number of factors, including (1) the quality of the DC vaccine and (2) tumor immune evasion. The recently characterized BDCA1+CD14+ immunosuppressive cells combine both aspects; their presence in DC vaccines may directly hamper vaccine efficacy, whereas, in patients, BDCA1+CD14+ cells may suppress the induced immune response in an antigen-specific manner systemically and at the tumor site. We hypothesize that BDCA1+CD14+ cells are present in a broad spectrum of cancers and demand further investigation to reveal treatment opportunities and/or improvement for DC vaccines. In this review, we summarize the findings on BDCA1+CD14+ cells in solid cancers. In addition, we evaluate the presence of BDCA1+CD14+ cells in leukemic cancers. Preliminary results suggest that the presence of BDCA1+CD14+ cells correlates with clinical features of acute and chronic myeloid leukemia. Future research focusing on the differentiation from monocytes towards BDCA1+CD14+ cells could reveal more about their cell biology and clinical significance. Targeting these cells in cancer patients may improve the outcome of cancer immunotherapy.Keywords
Funding Information
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (918.14.655)
- Fonds Wetenschappelijk Onderzoek (PhD fellowship)
This publication has 42 references indexed in Scilit:
- Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma PatientsCancer Research, 2013
- T-Regulatory Cells: Key Players in Tumor Immune Escape and AngiogenesisCancer Research, 2012
- Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammationJournal of Experimental Medicine, 2012
- Coordinated regulation of myeloid cells by tumoursNature Reviews Immunology, 2012
- Revisiting the Hallmarks of MidwiferyJournal of Midwifery & Women's Health, 2010
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophagesJournal of Clinical Investigation, 2007
- Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin testsAnnals of Oncology, 2006
- Dendritic cell immunotherapy: mapping the wayNature Medicine, 2004
- Natural selection of tumor variants in the generation of “tumor escape” phenotypesNature Immunology, 2002